Skip to content

Effects of Dietary Supplements on Autoimmune Diseases

Effects of Dietary Supplements on Autoimmune Diseases

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110535
Enrollment
Unknown
Registered
2025-10-15
Start date
2025-10-15
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

Flaxseed oil:Flaxseed oil supplement, daily oral administration per protocol (UFA 60mg/kg), up to 24 weeks.
Rosemary:Rosemary supplement, daily oral administration per protocol (30mg/kg), up to 24 weeks.
Olive oil:Olive oil supplement, daily oral administration per protocol (UFA 60mg/kg), up to 24 weeks.
Omega fatty acid:Omega fatty acid supplement, daily oral administration per protocol (UFA 60mg/kg), up to 24 weeks.
Rutin:Rutin supplement, daily oral administration per protocol (30mg/kg), up to 24 weeks.
Quercetin:Quercetin supplement, daily oral administration per protocol (30mg/kg), up to 24 weeks.

Sponsors

Tianjin Union Medical Centre
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients voluntarily agree to participate in this study, demonstrate good compliance, are able to follow study requirements to complete observation and follow-up, and have signed the informed consent form; 2.Age between 18 and 65 years at the time of signing the informed consent; 3.Clinically diagnosed with autoimmune disease, or age- and sex-matched healthy volunteers;

Exclusion criteria

Exclusion criteria: 1.Patients requiring high-dose immunosuppressants or biologic rescue therapy; 2.Patients with concomitant malignant tumors or severe cardiovascular diseases, or those currently receiving other treatments that may interfere with the study results; 3.Patients unable to take dietary supplements as scheduled, or with insufficient compliance to complete follow-up and testing; 4.Any other conditions deemed inappropriate for study participation based on medical judgment;

Design outcomes

Primary

MeasureTime frame
Change in disease activity score;

Secondary

MeasureTime frame
Safety of the intervention;Changes in immune cell function;Change in disease activity score;

Countries

China

Contacts

Public ContactLiu Yandi

Tianjin Union Medical Centre

liuyandi66@163.com+86 22 27557293

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026